barasertib-hQPA

Ligand id: 5663

Name: barasertib-hQPA

Structure and Physico-chemical Properties

2D Structure
Click here for structure editor
Calculated Physico-chemical Properties
Hydrogen bond acceptors 8
Hydrogen bond donors 4
Rotatable bonds 14
Topological polar surface area 128.29
Molecular weight 507.24
XLogP 3.02
No. Lipinski's rules broken 1

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
This drug is in Phase I clinical trial in patients with advanced solid tumors [6], although its use is limited by the need for continuous i.v. infusion. To overcome this limitation, a nanoparticle formulation of AZD1152-hQPA known as AZD2811 has been developed [3] and is being evaluated in early stage clinical trials for AML and some advanced solid tumours (see NCT03217838, NCT03366675 and NCT02579226 [1] for example) .
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02579226 A Phase I Study of Safety, Tolerability, and PK of AZD2811 in Patients With Advanced Solid Tumors. Phase 1 Interventional AstraZeneca
NCT03217838 Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Patients. Phase 1/Phase 2 Interventional AstraZeneca
NCT03366675 AZD 2811 Monotherapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N3] Phase 2 Interventional Samsung Medical Center